Back to today’s briefing

Story perspectives

Sage Therapeutics Cuts 338 Jobs Amid Supernus Acquisition

7/1/2025

47 9

Summary

Story summary

Sage Therapeutics will reduce its workforce by 338 employees on Aug. 22 due to its acquisition by Supernus Pharmaceuticals for $561 million.
This decision stems from ongoing financial difficulties and unsuccessful drug development efforts.
Prior to layoffs, Sage had 353 employees, including 122 in research and development.
The company is known for developing Zulresso and recently gained FDA approval for Zurzuvae.

1 of 1

Story summary

Sage Therapeutics will reduce its workforce by 338 employees on Aug. 22 due to its acquisition by Supernus Pharmaceuticals for $561 million.
This decision stems from ongoing financial difficulties and unsuccessful drug development efforts.
Prior to layoffs, Sage had 353 employees, including 122 in research and development.
The company is known for developing Zulresso and recently gained FDA approval for Zurzuvae.